Burning Rock Biotech (BNR) vs Insight Molecular Diagnostics (IMDX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Burning Rock Biotech (BNR) has outperformed Insight Molecular Diagnostics (IMDX) over the past year, gaining 80.5% versus a loss of 11.3%. Over five years, BNR leads with a -89.2% price change compared with -95.0% for IMDX. Burning Rock Biotech is the larger company by market cap ($163.4 million vs $110.3 million), about 1.5 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BNR | IMDX |
|---|---|---|
| Share price | $15.49 | $3.37 |
| Market cap | $163.36M | $110.28M |
| 1-day change | +3.27% | +2.74% |
| YTD return | -23.13% | -55.07% |
| 1-year return | +80.54% | -11.32% |
| 5-year return | -89.21% | -95.04% |
| EPS (TTM) | $-0.80 | $-1.52 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $41.72 | $8.51 |
| 52-week low | $6.79 | $2.42 |
| Distance from 52-week high | -62.87% | -60.40% |
| Analyst consensus | — | none |
| Avg. price target upside | — | +144.81% |
| Average volume | 28.59K | 232.87K |
| Shares outstanding | 8.81M | 32.72M |
| Employees | 667 | 55 |
| Sector | Health Care | Health Care |
| Industry | Medical Specialities | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- BNR has outperformed IMDX by 91.9 percentage points over the past year.
About Burning Rock Biotech
BNR stock →Burning Rock Biotech Limited develops and sells cancer therapy selection tests in the People's Republic of China and the United States. It operates in three segments: Central Laboratory Business, In-Hospital Business, and Pharma Research and Development Services.
Health Care · Medical Specialities · 667 employees
About Insight Molecular Diagnostics
IMDX stock →Insight Molecular Diagnostics Inc. operates as a precision diagnostics company in the United States and internationally.
Health Care · Biotechnology: In Vitro & In Vivo Diagnostic Substances · 55 employees
BNR vs IMDX FAQ
Which is bigger, Burning Rock Biotech or Insight Molecular Diagnostics?
Burning Rock Biotech (BNR) is larger, with a market capitalization of $163.36M compared with $110.28M for Insight Molecular Diagnostics (IMDX).
Which stock has performed better over the past year, BNR or IMDX?
BNR returned +80.54% over the past 12 months, compared with -11.32% for IMDX (price return, excluding dividends). Past performance does not predict future results.
Are Burning Rock Biotech and Insight Molecular Diagnostics in the same industry?
Both are in the Health Care sector, but in different industries: Medical Specialities for Burning Rock Biotech and Biotechnology: In Vitro & In Vivo Diagnostic Substances for Insight Molecular Diagnostics.